These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

763 related articles for article (PubMed ID: 15977970)

  • 41. Long-term pharmacotherapy of obesity 2000: a review of efficacy and safety.
    Glazer G
    Arch Intern Med; 2001 Aug 13-27; 161(15):1814-24. PubMed ID: 11493122
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
    Kiortsis DN
    Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
    Suplicy H; Boguszewski CL; dos Santos CM; do Desterro de Figueiredo M; Cunha DR; Radominski R
    Int J Obes (Lond); 2014 Aug; 38(8):1097-103. PubMed ID: 24287940
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Obesity drug therapy.
    Baretić M
    Minerva Endocrinol; 2013 Sep; 38(3):245-54. PubMed ID: 24126545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. New antiobesity agents in type 2 diabetes: overview of clinical trials with sibutramine and orlistat.
    Scheen AJ; Ernest P
    Diabetes Metab; 2002 Dec; 28(6 Pt 1):437-45. PubMed ID: 12522323
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug treatment of obesity.
    Bray GA
    Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Apr; 13(1):131-48. PubMed ID: 10932681
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sibutramine--a review of clinical efficacy.
    Lean ME
    Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S30-6; discussion 37-9. PubMed ID: 9130039
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Weight loss medications--where do they fit in?
    Dixon JB
    Aust Fam Physician; 2006 Aug; 35(8):576-9. PubMed ID: 16894428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.
    Richelsen B; Tonstad S; Rössner S; Toubro S; Niskanen L; Madsbad S; Mustajoki P; Rissanen A
    Diabetes Care; 2007 Jan; 30(1):27-32. PubMed ID: 17192328
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
    Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
    Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Orlistat--a novel weight loss therapy.
    Lucas KH; Kaplan-Machlis B
    Ann Pharmacother; 2001 Mar; 35(3):314-28. PubMed ID: 11261530
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Orlistat: a review of its use in the management of obesity.
    Hvizdos KM; Markham A
    Drugs; 1999 Oct; 58(4):743-60. PubMed ID: 10551441
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacotherapy of obesity: Available medications and drugs under investigation.
    Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
    Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration.
    Grabarczyk TR
    Pharmacotherapy; 2018 Jan; 38(1):19-28. PubMed ID: 29044720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug treatment for obesity in the post-sibutramine era.
    Cheung BM
    Drug Saf; 2011 Aug; 34(8):641-50. PubMed ID: 21751825
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the Efficacy of Anti-Obesity Medications in Real-World Practice.
    Song JE; Ko HJ; Kim AS
    Drug Des Devel Ther; 2024; 18():845-858. PubMed ID: 38524878
    [TBL] [Abstract][Full Text] [Related]  

  • 58. New and emerging drug molecules against obesity.
    George M; Rajaram M; Shanmugam E
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial.
    Wadden TA; Berkowitz RI; Womble LG; Sarwer DB; Arnold ME; Steinberg CM
    Obes Res; 2000 Sep; 8(6):431-7. PubMed ID: 11011909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.